The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Issue 6 (February 2019)

• Record Type: Journal Article
• Authors: He, Linye; Xia, Zijing; Shen, Junyi; Zhang, Xiaoyun; Peng, Wei; Li, Chuan; Wen, Tianfu
• Other Names: Bakir. Mehmet section editor.
• Is Part Of: Medicine. Volume 98:Issue 6(2019)
• Publication Date: 2019-02
• Subjects: adefovir disoproxil -- chronic hepatitis b -- hepatocellular carcinoma -- nucleo(t)side analogues -- telbivudine; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014386
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Numerous studies suggested that antiviral therapy could reduce the recurrence in hepatocellular carcinoma (HCC) patients after hepatectomy. The impact of nucleotide and nucleoside analogues on prognosis of chronic hepatitis B (CHB) related HCC remains to be explored. We aimed to investigate the role of the telbivudine and adefovir dipivoxil on the prognosis of CHB-related HCC patients after hepatectomy. One hundred eighty-eight CHB-related patients who received hepatectomy from February 2010 to February 2017 were divided into telbivudine (LdT) and adefovir dipivoxil (ADV) groups. The characteristics and survival information of both groups were retrospectively compared and analyzed. One hundred eleven and 77 patients received telbivudine and adefovir dipivoxil monotherapy, respectively. Alanine aminotransferase (ALT), total bilirubin level, status of hepatitis B e antigen (HBeAg), serum HBV-DNA level were compared between groups. OS and DFS in ADV-treatment group were significantly better than it in LdT-treatment group ( P < .05). In the subgroups analysis, we found that ADV treatment was significantly associated with better DFS and OS among patients with cirrhosis, HBeAg-negative patients, or those with detectable HBV-DNA. CHB-related HCC patients receiving long-term ADV-treatment had a better OS and DFS than patients receiving LdT-treatment after hepatectomy. Abstract : Supplemental Digital Content is available in the text